Publications

Read Now

September 1999 (Revised September 2005)
Case

Strategic Deal Making at Millennium Pharmaceuticals

A small start-up in 1993, Millennium Pharmaceuticals was a name-brand biotechnology company by the end of 1998, with a market capitalization of $1.4 billion. The Cambridge-based company's growth strategy had relied heavily on building alliances for early-stage drug... View Details

Keywords: Alliances; Negotiation Deal; Growth and Development Strategy; Pharmaceutical Industry; Cambridge

28 Sep 2020
Working Paper Summaries

What Can Economics Say About Alzheimer's Disease?

Keywords: by Amitabh Chandra, Courtney Coile, and Corina Mommaerts; Health; Pharmaceutical

August 1995 (Revised June 1997)
Case

Hillcrest Research Associates, Inc.

Hillcrest designs and administers testing procedures for drugs to determine whether they pass FDA specifications. As the company grows, it encounters problems with information technology and with the clinical research associates, who feel pressured to report more... View Details

Keywords: Growth Management; Information Technology; Health Testing and Trials; Pharmaceutical Industry

Find at Harvard

November 2022 (Revised April 2024)
Case

Martine Rothblatt and United Therapeutics: A Series of Implausible Dreams

By: Debora L. Spar and Julia M. Comeau

In 1990, satellite expert and Sirius XM founder Martine Rothblatt was determined to save the life of her seven-year-old daughter, Jenesis, who was diagnosed with a terminal illness called Pulmonary Arterial Hypertension (PAH). At the time, there was little medication... View Details

Keywords: Pharmaceutical Companies; Technological And Scientific Innovation; Organ Donation; Health Care and Treatment; Health Disorders; Innovation and Invention; Pharmaceutical Industry; Medical Devices and Supplies Industry; United States; District of Columbia

26 Jul 2016
Working Paper Summaries

The Impact of the Entry of Biosimilars: Evidence from Europe

Keywords: by Fiona Scott Morton, Ariel Dora Stern, and Scott Stern; Health; Biotechnology; Pharmaceutical

November 1993 (Revised January 2006)
Supplement

Beech-Nut Nutrition Corporation (B)

By: Lynn S. Paine

Officials of the U.S. Food and Drug Administration (FDA) must decide whether to refer the Beech-Nut apple juice case to the Justice Department for criminal prosecution, and if so, whether to recommend prosecution of individual executives or of the company only. View Details

Keywords: Crime and Corruption; Decisions; Cases; Law; Management; Food and Beverage Industry

January 2001
Case

Merck Global Health Initiatives (A)

By: James E. Austin, Diana Barrett and James Weber

The case series focuses on Merck's drug donation program and then raises new issues facing management about what to do about HIV/AIDS in Africa given the company's development of a new therapy. Describes collaboration among many parties including the Gates Foundation,... View Details

Keywords: Programs; Philanthropy and Charitable Giving; Health Disorders; Health Care and Treatment; Private Sector; Public Sector; Alliances; Problems and Challenges; Pharmaceutical Industry; Botswana

January 2021
Case

mPharma (A)

By: Rembrand Koning, John D. Macomber, Pippa Tubman Armerding and Wale Lawal

mPharma pioneered electronic prescriptions in Ghana, and aimed to increase drug affordability and accessibility in Africa, but the company remained unprofitable. Following investor concerns about mPharma's business, CEO Gregory Rockson considered alternative business... View Details

Keywords: Strategy; Entrepreneurship; Acquisition; Health; Business Model; Health Industry; Technology Industry; Ghana

October 2012
Supplement

Aqua Bounty Courseware

By: Lucy White and Steve Burn-Murdoch

Valuation of a pre-revenue biotech company at IPO using probability trees and real option techniques. Company is based in Massachusetts and lists in London on AIM. Products are genetically-modified fast-growing salmon for fish farmers and disease-prevention drugs and... View Details

Keywords: IPO; Valuation; Real Options; Decision Tree; Biotech; Genetically Modified; Salmon; Entrepreneurship; Finance; Agriculture and Agribusiness Industry; Biotechnology Industry; North and Central America; Europe; South America

February 2002 (Revised August 2002)
Case

Inhale Therapeutics: Executing and Growing the Business Model

Inhale is about to bring a novel technology to market that uses inhalation to administer drugs that formerly required injection. Inhale must now decide which way to evolve its business model. This will determine the future direction of growth for the company. View Details

Keywords: Business Model; Technological Innovation; Health Care and Treatment; Growth and Development Strategy; Medical Devices and Supplies Industry

Find at Harvard

September 1993
Supplement

Manufacturing at ALZA: The Right Prescription? (C)

By: Dorothy A. Leonard

ALZA, a drug delivery company, considers marketing its own and other companies' products. The primary issue is whether to build an internal sales force focused on a few niche markets, to finance a sales force through alliances, or to acquire a marketing company. View Details

Keywords: Mergers and Acquisitions; Product Marketing; Alliances; Research and Development; Salesforce Management; Business Strategy; Pharmaceutical Industry

Find at Harvard

06 Mar 2020
News

How Medical Nonprofits Set Winning Strategy

11 Oct 2011
Working Paper Summaries

US Healthcare Reform and the Pharmaceutical Industry

Keywords: by Arthur Daemmrich; Pharmaceutical; Health

12 Jul 2016
First Look

July 12, 2016

of Biosimilars: Evidence from Europe By: Scott Morton, Fiona, Ariel Dora Stern, and Scott Stern Abstract—Biologic (large-molecule) drugs represent a disproportionate and growing share of all drug spending in... View Details

Keywords: Sean Silverthorne

2024
Working Paper

Chimeric Antigen Receptor T-Cell Therapy—Living Drugs: Case Histories of Transformational Advances

By: Amar Bhidé and Srikant M. Datar

In 2017, the US Food and Drug Administration (FDA) approved an immunotherapeutic treatment, called CAR-T therapy, for two kinds of blood cancers—acute leukemia (ALL) and a lymphoma. We describe 1) how CAR-T works, 2) the foundational advances and discoveries, 3) the... View Details

Keywords: Immunotherapy; Health Care and Treatment; Innovation and Invention; Research and Development; Governing Rules, Regulations, and Reforms

SSRN

Read Now

May 2002 (Revised October 2005)
Case

Marketing Antidepressants: Prozac and Paxil

By: Youngme E. Moon and Kerry Herman

Describes the marketing of Prozac and Paxil, two of the best-selling mental health drugs in history. Set in 2001, several months before the expiration of Prozac's patent, Eli Lilly (Prozac's manufacturer) and GlaxoSmithKline (Paxil's manufacturer) must decide how to... View Details

Keywords: Patents; Product Positioning; Competition; Ethics; Value; Health Care and Treatment; Brands and Branding; Pharmaceutical Industry; United States

January 2001
Case

Merck Global Health Initiatives (B): Botswana

By: James E. Austin, Diana Barrett and James Weber

The case series focuses on Merck's drug donation program and then raises new issues facing management about what to do about HIV/AIDS in Africa given the company's development of a new therapy. Describes collaboration among many parties including the Gates Foundation,... View Details

Keywords: Health Disorders; Health Care and Treatment; Private Sector; Public Sector; Alliances; Problems and Challenges; Africa; Botswana